Sarah Coughlin explains her study and its findings: across all ages, panel sizes, and races/ethnicities, the rate of clinically actionable variants was 7.8 percent or greater – supporting an expanded role for multigene panel testing in CRC patients.
New stool- and blood-based tests have the potential to overcome some of the barriers of initial colonoscopy screening.
Optimizing waste management can significantly reduce the carbon footprint of endoscopies.
COVID-19 revealed the fragility of the clinical trial system and scientific publishing.
Dr. Chang outlines strategies for individuals and organizations to reduce burnout — such as finding ways to decrease the burden of administrative work.
Recognizing risks is the first step to identifying disease.
Dr. Tyler Berzin explores the current and future impacts of AI in gastroenterology.
More courses of antibiotics = increased risk, but the type of antibiotic mattered.
Dr. Gupta will present during two DDW sessions, covering disparities in CRC screening and policies for non-colonoscopy tests.
Get expert advice on how to get your research article published in Gastro Hep Advances from the co-editor, Shanthi Srinivasan, MD, AGAF.
